C. Abas

In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report

E. Zwarthoff, T. Zuiverloon, Kirstin A. van der Keur, 2010, BMC urology.

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.

T. H. van der Kwast, N. Malats, M. Márquez, 2020, European urology.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

T. Ørntoft, E. Steyerberg, N. Malats, 2014, European urology.

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.

A. Broeks, Y. Lotan, Y. Allory, 2021, Urologic oncology.